Analytical Data
-
Gene name
CYP2D6
- Application
-
Alternative Names
CYP2D6；CYP2DL1；Cytochrome P450 2D6
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P10635
-
Expression Region
236-472aa
-
AA Sequence
LAGKV LRFQKAFLTQ LDELLTEHRM TWDPAQPPRD LTEAFLAEME KAKGNPESSF NDENLRIVVA DLFSAGMVTT STTLAWGLLL MILHPDVQRR VQQEIDDVIG QVRRPEMGDQ AHMPYTTAVI HEVQRFGDIV PLGVTHMTSR DIEVQGFRIP KGTTLITNLS SVLKDEAVWE KPFRFHPEHF LDAQGHFVKP EAFLPFSAGR RACLGEPLAR MELFLFFTSL LQHFSFSVPT GQ
-
Molecular Weight
56 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP2D6, a member of the cytochrome P450 superfamily, plays a crucial role in the metabolism of a significant proportion of clinically used drugs, including antidepressants, antipsychotics, and analgesics. Variability in CYP2D6 activity is largely attributed to genetic polymorphisms, leading to distinct metabolizer phenotypes: poor, intermediate, extensive, and ultrarapid metabolizers. This genetic variability can significantly affect drug pharmacokinetics, therapeutic efficacy, and the risk of adverse drug reactions, making CYP2D6 a key target for personalized medicine. Research on recombinant CYP2D6 proteins aids in understanding the enzyme's structure-function relationships and its interaction with diverse substrates. By producing and characterizing recombinant CYP2D6, researchers can investigate the enzymatic mechanisms involved in drug metabolism, explore the effects of specific polymorphisms, and test novel pharmaceutical compounds. As the demand for tailored therapies increases, studies on CYP2D6 have become instrumental in optimizing drug dosing strategies and reducing the incidence of drug-drug interactions, ultimately enhancing patient safety and therapeutic outcomes. Understanding the complexities of CYP2D6 is not only vital for pharmacogenomics but also contributes to the broader field of drug development and regulatory science.
